Y Intercept Hong Kong Ltd Buys New Shares in Generation Bio Co. $GBIO

Y Intercept Hong Kong Ltd purchased a new position in Generation Bio Co. (NASDAQ:GBIO) during the second quarter, HoldingsChannel reports. The institutional investor purchased 148,186 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new position in shares of Generation Bio during the 1st quarter valued at about $36,000. Nuveen LLC purchased a new stake in Generation Bio in the first quarter valued at approximately $69,000. Finally, Acadian Asset Management LLC grew its holdings in Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares during the period. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Analyst Ratings Changes

GBIO has been the topic of a number of recent analyst reports. Wedbush downgraded shares of Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research note on Wednesday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Generation Bio in a research report on Wednesday, August 13th. Wall Street Zen downgraded Generation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group lifted their price objective on Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Generation Bio currently has an average rating of “Hold” and a consensus price target of $10.67.

Generation Bio Trading Up 1.8%

Shares of Generation Bio stock opened at $5.11 on Monday. Generation Bio Co. has a twelve month low of $3.00 and a twelve month high of $25.20. The stock has a market cap of $34.44 million, a price-to-earnings ratio of -0.55 and a beta of 2.51. The company has a fifty day moving average price of $5.95 and a 200 day moving average price of $4.89.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($3.18) by $2.36. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $0.66 million. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%. Analysts forecast that Generation Bio Co. will post -1.75 earnings per share for the current year.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.